Pipsqueak23

Follows small-cap biotech and some meme stocks

[Pipsqueak23 @Pipsqueak23]

@dropsseason 0x5f8D8db664b318A9e2CF35c609699BA61369Ee49

[Pipsqueak23 @Pipsqueak23]

@DCLBlogger @elonsdev

[Pipsqueak23 @Pipsqueak23]

@ConsortiumKey @GonzoApe @Etherlambos11 Holy crap thanks!!!

[Pipsqueak23 @Pipsqueak23]

@ConsortiumKey 27

[Wayne @wyv_123]

Ok biotwitter, need your help here. Wasn’t she one of the $ONCT trial doctors and presenters who was very excited about Cirmtuzumab results months ago? And CEO recently said naked mAb may be more valuable than ADC due to less toxicity. Hmm.

[Pipsqueak23 @Pipsqueak23]

@bheafey97 @semodough She is just acting (interim) in the position though. I mean questions about letting go of current CMO and if they have someone permanent in mind.

[Pipsqueak23 @Pipsqueak23]

@puttputt_stocks I don’t know the exact term/structure of the warrants. I doubt the company would need to force exercise as the warrants expire in about a year anyway. At expiry, if warrants are in the money, they will be exercised and company will get the proceeds of exercised warrants.

[Pipsqueak23 @Pipsqueak23]

@hmeisler Now if you have that chart I wouldn’t auction it, I would trash it

[Pipsqueak23 @Pipsqueak23]

@hmeisler Helene what do you do with all your old charts?

[Pipsqueak23 @Pipsqueak23]

@Thekennedycorp $SGLB the forecast was $8 million for FY2021. Trickle has a new video out w/CEO https://t.co/ODW3Uv00DJ Bit far fetched but comp’ing w $3Billion $MTLS

[Pipsqueak23 @Pipsqueak23]

@AlpBugraBasat @Robert13313519 Lol I’m talking to a doctor-troll on Twitter 😭. $TRIL one of the amazing rare ones to come back from dead, you can cherry-pick an old high on tons of biotechs to make your argument. Venture risks. I’m so stupid I should have sold under $1 if I remembered cd-47 “doesn’t work”!

[Pipsqueak23 @Pipsqueak23]

@Robert13313519 @AlpBugraBasat $tril Don’t listen to this guy. Billions of dollars in market cap gains and acquisitions in the cd-47 field, he still couldn’t possibly be wrong....

[Peter Suzman @Biomaven]

Strength after announcing an offering is still my single-best long-term biotech indicator. In fact the only technical indicator I pay the slightest attention to. $TRIL

[Pipsqueak23 @Pipsqueak23]

@SnackBioTech As far as I know, EsoCheck and competitor Cytosponge just give a + or - result and require endoscopy after a +. $PAVM has hinted at expanding lab capability to narrow down that result further. Game-changer it can happen. Hopefully timed with IVD/FDA approval in 2022

[Pipsqueak23 @Pipsqueak23]

@Varro_Analytics $tril something about how they almost fired the employee who kept saying their was no RBC binding. They believed he was doing something wrong, but data was correct. Lol

[Pipsqueak23 @Pipsqueak23]

@Varro_Analytics I recall previous CEO mentioning on a conference call they were lucky to gain this advantage, expected RBC binding, and called it a “fluke”

[Pipsqueak23 @Pipsqueak23]

@Doc_Steve_Brule @YallWoods @Biotech_SD Can you share? Thanks. Saw some concern about a Triterras advisor but couldn’t find anything further

[Gerry Doyle @mgerrydoyle]

I’ve found it. I’ve found the most american tweet https://t.co/1tVHqpM3XE

[Pipsqueak23 @Pipsqueak23]

@skiing2029 Did I read that correctly...